One of the few research projects to study the spread of prostate cancer to the bones using three-dimensional models of tissue-engineered bone is underway at QUT's Institute of Health and Biomedical Innovation (IHBI).

On Tuesday Dendreon (DNDN) announced positive results in a trial of Provenge in men with advanced prostate cancer. The trial, according to their press release, "met its primary endpoint of improving overall survival compared to a placebo control."

A newly discovered gene fusion is highly expressed in a subset of prostate cancers, according to a study by researchers at Weill Cornell Medical College.

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

Preliminary results show that a shortened course of radiation therapy for prostate cancer called stereotactic body radiation therapy (SBRT) provides good PSA response for early-stage prostate cancer and has the same side effects as other treatments, according to a March 15 study in the International Journal of Radiation Oncology Biology Physics, the official journal of the American Society for Radiation Oncology.

New research findings out of Wake Forest University School of Medicine and the University of Wisconsin may help provide some direction for men diagnosed with prostate cancer about whether their cancer is likely to be life-threatening.

DHEA is a natural circulating hormone and the body's production of it decreases with age. Men take DHEA as an over-the-counter supplement because it has been suggested that DHEA can reverse aging or have anabolic effects since it can be metabolized in the body to androgens.

Scientists at Melbourne's Burnet Institute have developed a potential new treatment for patients with prostate cancer. An article, which described the invention, has recently been published in the prestigious international journal The Journal of Clinical Investigation.

A new study appearing in The Prostate has found that certain measles virus vaccine strain derivatives, including a strain known as MV-CEA, may prove to be an effective treatment for patients with advanced prostate cancer. The findings show that this type of treatment, called virotherapy, can effectively infect, replicate in and kill prostate cancer cells.

In a first of its kind study, a first-degree family history of prostate cancer has no impact on the treatment outcomes of prostate cancer patients treated with brachytherapy (also called seed implants), and patients with this type of family history have clinical and pathologic characteristics similar to men with no family history at all, according to a January 1 study in the official journal of the American Society for Radiation Oncology.

More than 95 per cent of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the December issue of BJU International.

Prostate cancer – and perhaps other cancers – promotes the growth of new nerves and the branching axons that carry their messages, a finding associated with more aggressive tumors, said researchers from Baylor College of Medicine in the first report of the phenomenon that appears today in the journal Clinical Cancer Research.